Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T22:31:22.198Z.
Calculation as of: 2026-10-06T22:31:22.198Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f1b6469add1457cabf137e6e5cfb012e486d3d2c84b47330ed8a9effb8bf14c7
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$63.78M
EV/Sales Ratio
N/A
TTM Avg
928.39x
3Y Avg
361.42x
5Y Avg
265.11x
Market Cap
$68.10M
EV/Sales Ratio
N/A
TTM Avg
1.19x
3Y Avg
0.71x
5Y Avg
0.83x
Market Cap
$68.90M
EV/Sales Ratio
0.47x
TTM Avg
1.76x
3Y Avg
1.34x
5Y Avg
5.36x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cingulate Inc. (CING) | $65.86M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $65.87M | 1.20x | 9.45x | 7.55x | 7.55x |
| XBiotech Inc. (XBIT)vs › | $65.85M | N/A | 4.89x | 5.40x | 8.24x |
| iBio, Inc. (IBIO)vs › | $67.52M | 133.26x | 409.50x | 278.27x | 209.69x |
| Alps Group Inc (ALPS)vs › | $64.18M | N/A | N/A | N/A | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.78M | N/A | 928.39x | 361.42x | 265.11x |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | N/A | 1.19x | 0.71x | 0.83x |
| InterCure Ltd. (INCR)vs › | $63.02M | 1.33x | 1.24x | 1.42x | 1.83x |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 0.47x | 1.76x | 1.34x | 5.36x |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.78M | 1.26x | 1.74x | 2.85x | 4.03x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
